Italia markets close in 12 minutes

Chr. Hansen Holding A/S (0MR6.IL)

IOB - IOB Prezzo differito. Valuta in DKK.
Aggiungi a watchlist
502,00+9,00 (+1,83%)
Al 03:46PM GMT. Mercato aperto.
Schermo intero
Caricamento grafico interattivo in corso...
  • GlobeNewswire

    Notice to convene Extraordinary General Meeting

    MARCH 8, 2023 – ANNOUNCEMENT NO. 4 An Extraordinary General Meeting of Chr. Hansen Holding A/S will be held on Thursday, March 30, 2023, at 5:00 p.m. CEST at The Hangar – Clarion Hotel & Congress Copenhagen Airport, Ellehammersvej 20, DK-2770 Kastrup, Denmark. The notice to convene the Extraordinary General Meeting, including annex 1 “Articles of Association”, is enclosed. For further information please contact: Anders Mohr Christensen, Vice President Group Strategy & Investor Relations, Tel: +4

  • GlobeNewswire

    Publication of exemption document in relation to the proposed combination of Chr. Hansen and Novozymes, confirmation of outlook for 2022/23 and proposed candidates to the Board of Directors of the combined company

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART), IN OR INTO THE UNITED STATES, CANADA, SOUTH AFRICA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION WHERE SUCH ACTION WOULD BE UNLAWFUL. March 8, 2023 – Company announcement no. 3 On December 12, 2022, Novozymes A/S ("Novozymes") and Chr. Hansen Holding A/S ("Chr. Hansen") announced that Novozymes and Chr. Hansen had entered into a merger agreement to combine by way of a statutory merger of the two companies

  • GlobeNewswire

    Novozymes and Chr. Hansen receive binding tax ruling that the proposed merger can be completed as a tax-exempt merger

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART), IN OR INTO THE UNITED STATES, CANADA, SOUTH AFRICA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION WHERE SUCH ACTION WOULD BE UNLAWFUL. JANUARY 24, 2023 On December 12, 2022, Novozymes A/S ("Novozymes") and Chr. Hansen Holding A/S ("Chr. Hansen") announced that Novozymes and Chr. Hansen propose to combine and create a leading global biosolutions partner by way of a statutory merger of the two companies (the